Ionis Pharmaceuticals (IONS) Common Equity (2009 - 2026)

Ionis Pharmaceuticals' Common Equity history runs 18 years deep, the most recent figure standing at $491.4 million for Q1 2026.

• In Q1 2026, Common Equity rose 3.3% year-over-year to $491.4 million; the TTM figure through Mar 2026 stood at $491.4 million (up 3.3% YoY), while the FY2025 annual figure was $489.1 million, down 16.87% from the prior year.
• Common Equity was $491.4 million for Q1 2026 at Ionis Pharmaceuticals, roughly flat from $489.1 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $709.6 million in Q1 2022 to a low of $263.7 million in Q2 2024.
• Historically, Common Equity has averaged $508.0 million across 5 years, with a median of $491.4 million in 2026.
• The sharpest annual moves came in 2023 and 2025: Common Equity tumbled 46.92% in 2023, then soared 139.56% in 2025.
• A 5-year view of Common Equity shows it stood at $572.9 million in 2022, then sank by 32.5% to $386.7 million in 2023, then soared by 52.15% to $588.4 million in 2024, then fell by 16.87% to $489.1 million in 2025, then grew by 0.48% to $491.4 million in 2026.
• The last three Common Equity figures came in at $491.4 million (Q1 2026), $489.1 million (Q4 2025), and $618.0 million (Q3 2025), per Business Quant data.